NDONOVO THERAPEUTICS INC - ENDV STOCK NEWS

Endonovo Therapeutics (OTCQB: ENDV) has launched an international initiative to expand the sales of its SofPulse® medical devices. President Ira Weisberg is negotiating with partners in South America, Australia, Europe, and Southeast Asia. The company anticipates regulatory approval in Taiwan by mid-2023, opening significant market opportunities given over a million surgeries performed annually. Weisberg aims for SofPulse® to become a standard in post-surgical pain management, targeting over $100 million in sales by 2024.

Endonovo Therapeutics has announced a spin-off of its medical device assets related to the SofPulse® line, creating a new entity led by Ira Weisberg, who will operate independently. The spin-off aims to enhance commercialization efforts while potentially generating a pre-money valuation exceeding $50 million. 20% of shares may be allocated to satisfy existing debt holders, with NewCo targeting over $100 million in sales by 2024. The fairness opinion report will guide the transaction, with plans for potential NASDAQ listing.

Endonovo Therapeutics (OTCQB: ENDV) launched a telehealth initiative aimed at providing education and access to non-opioid pain management solutions. This platform will facilitate the distribution of their FDA-cleared SofPulse^® device, which reduces the need for opioids in treating pain. With a growing shortage of healthcare professionals and rising demand for alternative pain management options, Endonovo seeks to educate communities about non-pharmacological treatments. The U.S. telehealth market is projected to grow at a CAGR of 44.4% from 2022 to 2028, highlighting significant market potential.

Endonovo Therapeutics (OTCQB: ENDV) has appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg will lead global sales and marketing, focusing on expanding the SofPulse® and Roma® Pulsed Electro Magnetic Frequency (PEMF) medical devices. With over 40 years in healthcare and pharmaceutical management, his previous roles include significant positions at Amherst Pharmaceuticals and AVENTIS BEHRING. Weisberg aims to generate over $100 million in revenues through a robust growth strategy, enhancing Endonovo’s market reach and shareholder value.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) plans to explore strategic alternatives to maximize shareholder value for its SofPulse® PEMF assets. This initiative may involve discussions with investment bankers, equity fund managers, and medical technology consultants. CEO Alan Collier expressed confidence in expanding distribution channels and commercializing SofPulse®, which has shown positive clinical effects on various inflammatory diseases. The company aims to partner with global medical device participants for growth, focusing on joint ventures and licensing agreements.

Endonovo Therapeutics (OTCQB: ENDV) has updated its shareholders about its ongoing "Build Up Strategy," aimed at acquiring specialty service providers in the construction industry. This strategy targets companies with $12 to $100 million in annual revenues and 15% to 30% EBITDA margins. Currently, the company has a purchase agreement with Western Star Concrete and is in discussions with two other acquisition targets. Each target reportedly generates around $50 million in revenue and $5 to $6.3 million in EBITDA. This move is designed to bolster revenues and shareholder value in the long term.

Endonovo Therapeutics has signed a definitive purchase agreement to acquire all assets and operations of Western Star Concrete, a profitable Texas concrete construction company. This acquisition, expected to close by December 15, 2022, is projected to significantly enhance Endonovo's position in the specialty concrete sector. Western Star generates annual operating profits of $6.3 million, with anticipated revenues between $30 million and $60 million. The strategic acquisition will facilitate a projected 15% to 20% annual growth rate, expanding Endonovo’s footprint in the Southeast U.S.

Endonovo Therapeutics has released new comparative results showing that its SofPulse® medical device outperforms Bioelectronics RecoveryRx® in post-operative pain relief. Clinical evaluations indicate SofPulse® achieves medical efficacy in under 18 hours compared to RecoveryRx®, which requires 7 to 14 days of treatment. SofPulse® also offers a larger treatment area (285 cm vs. 110 cm) and deeper penetration (12.7 cm vs. 7.7 cm), making it significantly more effective. Moreover, SofPulse® provides over 10,000 times more peak spatial power, enhancing its therapeutic effects.

Endonovo Therapeutics (OTCQB:ENDV) announced a comparative analysis showing that its SofPulse® device outperforms leading pharmaceutical options for post-operative pain management. The study included Pacira BioSciences' Exparel®, Avanos Medical's On-Q®, and Mallinckrodt's Ofirmev®, which do not reduce edema post-surgery.

SofPulse® is FDA-cleared for both pain and edema reduction and is non-invasive, showcasing a 2.2X reduction in opioid use. CEO Alan Collier emphasized the device's effectiveness and potential cost savings in surgical pain management.